Aridis Pharmaceuticals Inc (NASDAQ:ARDS) Sellers Covered 92.25% of Their Shorts

September 16, 2018 - By Ash Ash

The stock of Aridis Pharmaceuticals Inc (NASDAQ:ARDS) registered a decrease of 92.25% in short interest. ARDS’s total short interest was 2,000 shares in September as published by FINRA. Its down 92.25% from 25,800 shares, reported previously. With 32,000 shares average volume, it will take short sellers 0 days to cover their ARDS’s short positions. The short interest to Aridis Pharmaceuticals Inc’s float is 2.08%.

The stock decreased 5.43% or $0.69 during the last trading session, reaching $12.01. About 13,651 shares traded. Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) has 0.00% since September 16, 2017 and is . It has underperformed by 15.62% the S&P500.

Aridis Pharmaceuticals Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies to treat life-threatening infections. The company has market cap of $94.76 million. The Company’s lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. It currently has negative earnings. The firm is also developing AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb that is in Phase IIa trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 to treat infections caused by A. baumannii; AR-201, an anti- respiratory syncytial virus F-protein mAb; and AR-501, an anti-infective therapy to manage chronic lung infections in cystic fibrosis patients and acute pneumonia in HAP and VAP patients.

More notable recent Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) news were published by: Benzinga.com which released: “The Week Ahead: Apple’s Special Event, Mobile World Congress, US Inflation Data On Deck” on September 10, 2018, also Bizjournals.com with their article: “Bay Area’s 10th life science IPO this year raises $26M as No. 11 hopes to fetch $86M” published on August 20, 2018, 247Wallst.com published: “IPO News This Week: Little Action Last Week, but That Will Change Soon” on August 19, 2018. More interesting news about Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) were released by: Benzinga.com and their article: “Benzinga’s Top Upgrades, Downgrades For September 10, 2018” published on September 10, 2018 as well as Seekingalpha.com‘s news article titled: “Stocks To Watch: Apple Event, Chinese Auto IPO To Headline” with publication date: September 08, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: